We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -10.00% | 9.00 | 8.00 | 10.00 | 9.00 | 9.00 | 9.00 | 156,071 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.06 | 35.01M |
TIDMREDX
RNS Number : 2669P
Redx Pharma plc
06 February 2019
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
REDX PHARMA PLC
("Redx" or "the Company")
Redx confirms receipt of outstanding loan
Alderley Park, 06 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, following the sale of significant assets by Redag Crop Protection Ltd (Redag), the repayment criteria for a loan previously granted to Redag by Redx in October 2014 has been met.
As a result, Redx confirms that it has now received a full cash repayment of GBP869,126, representing the original capital amount of GBP713,948 plus outstanding interest to date.
As disclosed in note 17 to the Accounts for the year ended 30 September 2018, the loan was originally treated as a non-current receivable, subsequently impaired, and ultimately derecognised as an asset in the accounts for the year ended 30 September 2017 as a result of the conditionality attached to the repayment. Notwithstanding this, the directors continued to seek repayment and are pleased that this has now been achieved. The funds will be used to augment working capital.
Accordingly the cash receipt will be disclosed in the statement of comprehensive income for the year ending 30 September 2019.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469 920 Lisa Anson, Chief Executive Officer Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894 Joint Broker) 7000 Phil Davies WG Partners LLP (Joint Broker) T: +44 20 3705 9330 Claes Spång/ Chris Lee/ David Wilson FTI Consulting T: +44 20 3727 1000 Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCCKADBDBKDBBK
(END) Dow Jones Newswires
February 06, 2019 06:25 ET (11:25 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions